SAH
Based on 20 publication(s) in Google Scholar
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 979-92-0
- Formule: C14H20N6O5S
- Masse moléculaire:384.41
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Nucleotide Compound Library
HY-L044
-
Gut Microbial Metabolite Library
HY-L078
-
Microbial Metabolite Library
HY-L084
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Animal-Sourced Natural Product Library
HY-L157
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Amino Acid Metabolite Compound Library
HY-L227
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) SAH
More- Cell Res. 2026 Feb;36(2):152-172. [Abstract]
- Redox Biol. 2024 Aug 17:76:103312. [Abstract]
- Adv Sci (Weinh). 2025 Mar 24:e2501623. [Abstract]
- Cancer Lett. 2025 Oct 2:218073. [Abstract]
- J Hazard Mater. 2025 Jan 28:488:137432. [Abstract]
- J Crohns Colitis. 2026 Feb 5;20(2):jjag003. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Oct 28;122(43):e2510386122. [Abstract]
- Dev Cell. 2026 Mar 12:S1534-5807(26)00079-1. [Abstract]
- Apoptosis. 2022 Jun;27(5-6):426-440. [Abstract]
- Mol Med. 2023 Jul 3;29(1):86. [Abstract]
- Ecotoxicol Environ Saf. 2026 Mar 15:313:119887. [Abstract]
- Commun Biol. 2025 Apr 8;8(1):582. [Abstract]
- Eur J Pharmacol. 2024 Aug 21:981:176908. [Abstract]
- Int J Mol Sci. 2024 Jan 5;25(2):733. [Abstract]
- Cell Signal. 2025 Jan 16:127:111610. [Abstract]
- Chem Res Toxicol. 2025 Mar 26. [Abstract]
- J Chromatogr A. 2025 May 10:1755:466036. [Abstract]
- Bone. 2022 Jan;154:116182. [Abstract]
- Oncol Lett. 2021 Oct;22(4):711. [Abstract]
- bioRxiv. 2023 Apr 19.
Customer Validation & Images
-
WB
-
IHC
-
IHC
-
IHC
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
0.14 μM
Compound: SAH
|
Inhibition of DOTL1 (unknown origin) using [3H]SAM and HeLa oligo nucleosomes as substrates incubated for 1 hr
Inhibition of DOTL1 (unknown origin) using [3H]SAM and HeLa oligo nucleosomes as substrates incubated for 1 hr
|
[PMID: 35525212] |
| Sf9 | IC50 |
>50 μM
Compound: SAH
|
Inhibition of human full length DNMT3A expressed in Sf9 cells
Inhibition of human full length DNMT3A expressed in Sf9 cells
|
[PMID: 25893041] |
| Sf9 | IC50 |
>50 μM
Compound: SAH
|
Inhibition of human full length DNMT3B expressed in Sf9 cells
Inhibition of human full length DNMT3B expressed in Sf9 cells
|
[PMID: 25893041] |
| Sf9 | IC50 |
>50 μM
Compound: SAH
|
Inhibition of human full length PRMT5 expressed in Sf9 cells
Inhibition of human full length PRMT5 expressed in Sf9 cells
|
[PMID: 25893041] |
| Sf9 | IC50 |
>50 μM
Compound: SAH
|
Inhibition of human full length PRMT7 expressed in Sf9 cells
Inhibition of human full length PRMT7 expressed in Sf9 cells
|
[PMID: 25893041] |
| Sf9 | IC50 |
1.9 μM
Compound: 1, SAH
|
Inhibition of N-terminally FLAG-tagged EZH2 Y641N mutant in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence o
Inhibition of N-terminally FLAG-tagged EZH2 Y641N mutant in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence o
|
[PMID: 25746813] |
| Sf9 | IC50 |
11 μM
Compound: 1, SAH
|
Inhibition of N-terminally FLAG-tagged wild type EZH2 in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence of [
Inhibition of N-terminally FLAG-tagged wild type EZH2 in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence of [
|
[PMID: 25746813] |
| Sf9 | IC50 |
4 μM
Compound: SAH
|
Inhibition of human recombinant DNMT1 expressed in Sf9 cells assessed as incorporation of [3H]S-adenosyl methionine into hemimethylated oligonucleotide substrate after 3 hrs by scintillation counting
Inhibition of human recombinant DNMT1 expressed in Sf9 cells assessed as incorporation of [3H]S-adenosyl methionine into hemimethylated oligonucleotide substrate after 3 hrs by scintillation counting
|
[PMID: 21958292] |
SAH (10-7-10-5 M) activates norepinephrine (NE) and serotonin (5-HT) in vitro uptake in synaptosomal preparations from rat brain, but does not affect dopamine (DA) uptake[1].
SAH (0.1-10 μM) shows strong inhibitory effects on METTL3-14 activity with an IC50 value of 0.9 μM in Kinetic parameter determination of the METTL3-14 complex[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
SAH (intraperitoneal injection; 7 mg/kg; 1 h prior to sacrifice) induces in vitro uptake increase for NE and 5-HT, significant only in brain stem and midbrain, but does not alter DA uptake[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 979-92-0
-
Appearance Solid
-
Masse moléculaire 384.41
-
Formule C14H20N6O5S
-
Color White to off-white
-
SMILES
NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CSCC[C@H](N)C(O)=O)[C@@H](O)[C@H]3O
-
Synonyms
SAH (S-Adenosylhomocysteine)
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis. [Abstract]2026 Feb;36(2):152-172. PMID: 41549122 -
Redox Biol
Plin4 exacerbates cadmium-decreased testosterone level via inducing ferroptosis in testicular Leydig cells. [Abstract]2024 Aug 17:76:103312. PMID: 39173539
SAH purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Aug 17:76:103312. [Abstract]
SAH (10 μM) intervention markedly alleviated environmental stress-induced elevation of PLIN4 levels and accumulation of lipid droplets.
-
Adv Sci (Weinh)
Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer. [Abstract]2025 Mar 24:e2501623. PMID: 40125618
SAH purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar 24:e2501623. [Abstract]
Immunoblotting analysis of PCSK9 in SW480 (upper panel) and SW620 (lower panel) cells with methionine deprivation for 6 h and then SAM E) or SAH F) supplementation for 24h.
-
Cancer Lett
2025 Oct 2:218073. PMID: 41045985 -
J Hazard Mater
Heat stress enhances the expression of METTL3 to mediate N6-methyladenosine modification of SOS2 and NLRP3 inflammasome activation in boar Sertoli cells. [Abstract]2025 Jan 28:488:137432. PMID: 39884044 -
J Crohns Colitis
Intermittent ketogenic diet promotes Treg differentiation and alleviates Crohn's disease via the β-hydroxybutyrate driven AHCY-DNMT1-Foxp3 axis. [Abstract]2026 Feb 5;20(2):jjag003. PMID: 41527294 -
Proc Natl Acad Sci U S A
A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression. [Abstract]2025 Oct 28;122(43):e2510386122. PMID: 41129231 -
Dev Cell
2026 Mar 12:S1534-5807(26)00079-1. PMID: 41825439 -
Apoptosis
2022 Jun;27(5-6):426-440. PMID: 35503144 -
Mol Med
2023 Jul 3;29(1):86. PMID: 37400752
SAH purchased from MedChemExpress. Usage Cited in: Mol Med. 2023 Jul 3;29(1):86. [Abstract]
The results of HE, PAS, and safranin O-fast green revealed that the cartilage damage and fibrosis induced by ACL-T were mitigated because of METTL3 inhibitor SAH (10 mg/kg).
-
Ecotoxicol Environ Saf
Bisphenol A disrupts circadian locomotor rhythms via m6A-dependent nr1d1 destabilization in zebrafish larvae. [Abstract]2026 Mar 15:313:119887. PMID: 41797106 -
Commun Biol
METTL3 obstructs vascular smooth muscle cells osteogenic reprogramming by methylating Runx2 in chronic kidney disease. [Abstract]2025 Apr 8;8(1):582. PMID: 40200050
SAH purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Apr 8;8(1):582. [Abstract]
METTL3 was effectively decreased in the VSMCs of SAH (S-Adenosylhomocysteine, 5 mg/kg, twice a week) treated CKD rats, accompanied with the elevation of Runx2 at the same localization.
-
Eur J Pharmacol
Single-cell sequencing reveals that specnuezhenide protects against osteoporosis via activation of METTL3 in LEPR+ BMSCs. [Abstract]2024 Aug 21:981:176908. PMID: 39154827 -
Int J Mol Sci
Melatonin Alleviates Lipopolysaccharide-Induced Abnormal Pregnancy through MTNR1B Regulation of m6A. [Abstract]2024 Jan 5;25(2):733. PMID: 38255808 -
Cell Signal
METTL14-mediated m6A modification of TRPA1 promotes acute visceral pain induced by uterine cervical dilation by promoting NR2B phosphorylation. [Abstract]2025 Jan 16:127:111610. PMID: 39826676 -
Chem Res Toxicol
RNA Methylation and Transcriptome Analysis Reveal Key Regulatory Pathways Related to Cadmium-Induced Liver Damage. [Abstract]2025 Mar 26. PMID: 40135526 -
J Chromatogr A
Quantification of five intracellular and extracellular methionine pathway intermediates using stable isotope dilution UHPLC-MS/MS. [Abstract]2025 May 10:1755:466036. PMID: 40398135 -
Bone
Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification. [Abstract]2022 Jan;154:116182. PMID: 34530171 -
Oncol Lett
RNA m6A methyltransferase METTL3 promotes colorectal cancer cell proliferation and invasion by regulating Snail expression. [Abstract]2021 Oct;22(4):711. PMID: 34457066 -
Solvant et solubilité
DMSO : 100 mg/mL (260.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. DE LA HABA G, et al. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem. 1959 Mar;234(3):603-8. [Content Brief]
[2]. Li F, et al. A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5. Biomol Screen. 2016 Mar;21(3):290-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6014 mL | 13.0069 mL | 26.0139 mL | 65.0347 mL |
| 5 mM | 0.5203 mL | 2.6014 mL | 5.2028 mL | 13.0069 mL | |
| 10 mM | 0.2601 mL | 1.3007 mL | 2.6014 mL | 6.5035 mL | |
| 15 mM | 0.1734 mL | 0.8671 mL | 1.7343 mL | 4.3356 mL | |
| 20 mM | 0.1301 mL | 0.6503 mL | 1.3007 mL | 3.2517 mL | |
| 25 mM | 0.1041 mL | 0.5203 mL | 1.0406 mL | 2.6014 mL | |
| 30 mM | 0.0867 mL | 0.4336 mL | 0.8671 mL | 2.1678 mL | |
| 40 mM | 0.0650 mL | 0.3252 mL | 0.6503 mL | 1.6259 mL | |
| 50 mM | 0.0520 mL | 0.2601 mL | 0.5203 mL | 1.3007 mL | |
| 60 mM | 0.0434 mL | 0.2168 mL | 0.4336 mL | 1.0839 mL | |
| 80 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8129 mL | |
| 100 mM | 0.0260 mL | 0.1301 mL | 0.2601 mL | 0.6503 mL |
SAH Related Classifications
HY-19528 Related Classifications
Powered by Bioz